Metformin, SGLT2 and DPP-4 Inhibitors: GPAT Exam Guide

Introduction to Modern Antidiabetic Therapy

Type 2 diabetes mellitus (T2DM) is characterized by progressive insulin resistance and beta-cell dysfunction. Managing blood glucose levels requires medications that target different metabolic pathways. Among modern oral antidiabetic drugs, three drug classes stand out: biguanides (metformin), sodium-glucose co-transporter 2 (SGLT2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors.

For pharmacy and medical students preparing for GPAT, NIPER, and board examinations, questions frequently focus on molecular targets, organ-specific benefits, dose adjustments, and distinct adverse effect profiles.

---

Metformin: The First-Line Biguanide

Metformin remains the universally recommended first-line oral hypoglycemic drug for type 2 diabetes unless specific contraindications exist.

Mechanism of Action

• AMPK Activation: Metformin activates adenosine monophosphate-activated protein kinase (AMP-activated protein kinase or AMPK) in hepatocytes.
• Inhibition of Gluconeogenesis: Activated AMPK suppresses the expression of key gluconeogenic genes, reducing hepatic glucose output.
• Peripheral Insulin Sensitivity: It enhances peripheral glucose uptake and utilization in skeletal muscle by promoting GLUT4 transporter translocation.
• Intestinal Glucose Absorption: It delays intestinal glucose absorption and increases anaerobic glycolysis in the gut wall.
• Insulin-Independent: Metformin does not stimulate insulin secretion from pancreatic beta cells. Therefore, it does not cause hypoglycemia when used as monotherapy.

Standard Doses and Administration

• Starting dose: 500 mg orally once or twice daily with meals to minimize gastrointestinal discomfort.
• Maintenance dose: 1500 mg to 2000 mg daily in divided doses.
• Maximum dose: 2550 mg per day.

Adverse Effects and Clinical Pearls

• Gastrointestinal Disturbance: Anorexia, nausea, abdominal cramps, and osmotic diarrhea affect up to 20% of patients.
• Vitamin B12 Deficiency: Long-term therapy reduces intestinal absorption of vitamin B12 by interfering with calcium-dependent membrane action in the ileum.
• Lactic Acidosis: A rare but fatal complication caused by the inhibition of mitochondrial respiration and gluconeogenesis from lactate. It is contraindicated if the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m².

---

SGLT2 Inhibitors: The Gliflozins

SGLT2 inhibitors are oral hypoglycemic agents that work through an insulin-independent renal pathway. Common drugs include empagliflozin, dapagliflozin, and canagliflozin.

Mechanism of Action

• Inhibition of Renal Glucose Reabsorption: SGLT2 is a high-capacity, low-affinity transporter located in the S1 segment of the renal proximal convoluted tubule (PCT). It reabsorbs roughly 90% of filtered glucose.
• Glucosuria: Gliflozins selectively inhibit SGLT2, lowering the renal threshold for glucose and promoting the excretion of 60 to 80 grams of glucose in urine daily.
• Secondary Benefits: Glucosuria leads to net caloric loss (weight loss) and osmotic diuresis (mild reduction in systolic blood pressure).

Standard Doses

• Empagliflozin: 10 mg orally once daily in the morning; can be increased to 25 mg once daily.
• Dapagliflozin: 10 mg orally once daily.
• Canagliflozin: 100 mg orally once daily before the first meal; max 300 mg daily.

Adverse Effects and Clinical Pearls

• Genital Mycotic Infections: Vulvovaginal candidiasis in women and balanitis in men due to glucosuria.
• Urinary Tract Infections (UTIs): Increased risk of bacterial cystitis.
• Euglycemic Diabetic Ketoacidosis (euDKA): Can present with near-normal blood glucose levels (<250 mg/dL), triggered by illness, surgery, or low carbohydrate intake.
• Cardio-Renal Protection: Proven to reduce heart failure hospitalizations and slow the progression of chronic kidney disease (CKD).

---

DPP-4 Inhibitors: The Gliptins

DPP-4 inhibitors are oral incretin enhancers that augment endogenous physiological glucose regulation. Key members include sitagliptin, vildagliptin, linagliptin, and saxagliptin.

Mechanism of Action

• Inhibition of DPP-4 Enzyme: Incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released by intestinal L and K cells after meals. DPP-4 rapidly degrades them.
• Prolonged Incretin Action: Gliptins competitively block the DPP-4 enzyme, extending the biological half-life of GLP-1 and GIP.
• Glucose-Dependent Action: Elevated incretins stimulate insulin release from beta cells and suppress glucagon release from alpha cells only when blood glucose is elevated.
• Weight Neutrality: Unlike GLP-1 receptor agonists, DPP-4 inhibitors do not significantly delay gastric emptying or promote satiety; hence, they are weight-neutral.

Standard Doses

• Sitagliptin: 100 mg orally once daily.
• Vildagliptin: 50 mg orally twice daily.
• Linagliptin: 5 mg orally once daily.
• Saxagliptin: 2.5 mg to 5 mg orally once daily.

Adverse Effects and Clinical Pearls

• Pancreatitis: Rare post-marketing reports of acute pancreatitis.
• Nasopharyngitis & Headache: Commonly reported mild upper respiratory symptoms.
• Joint Pain: Severe, disabling arthralgia has been observed.
• Renal Sparing Feature: Linagliptin is eliminated mainly via the enterohepatic/biliary route and requires no dose adjustment in renal impairment.

---

Comparative Pharmacology Chart

Feature	Metformin (Biguanide)	SGLT2 Inhibitors (Gliflozins)	DPP-4 Inhibitors (Gliptins)
Primary Target	AMPK activation / Hepatic mitochondria	SGLT2 transporter in renal PCT	Dipeptidyl peptidase-4 enzyme
Effect on Weight	Modest weight loss or neutral	Significant weight loss (caloric loss)	Weight neutral
Hypoglycemia Risk	Very low (monotherapy)	Very low (monotherapy)	Very low (glucose-dependent)
Cardiovascular Impact	Neutral / Potential long-term benefit	Proven reduction in HF hospitalizations	Neutral (Saxagliptin increases HF risk)
Elimination Route	Renal (active tubular secretion)	Hepatic metabolism / Renal	Linagliptin: Biliary; Others: Renal
Key Adverse Effects	Diarrhea, lactic acidosis, B12 drop	Genital candidiasis, euDKA, dehydration	Nasopharyngitis, joint pain, pancreatitis

---

High-Yield Points for GPAT & NIPER

• SGLT1 vs. SGLT2: SGLT1 is located mainly in the small intestine (reabsorbs glucose and galactose); SGLT2 is found in the S1 segment of the renal PCT.
• Canagliflozin Unique Warning: Previously carried an FDA black box warning regarding an increased risk of lower limb amputations.
• Linagliptin Advantage: Linagliptin is the only major DPP-4 inhibitor that can be prescribed at full dose without dose titration in patients with renal failure.
• Metformin Contraindication Cutoff: Avoid initiating metformin if eGFR is 30–45 mL/min/1.73 m²; completely contraindicated if eGFR is <30 mL/min/1.73 m².
• Euglycemic DKA Marker: Always test urine or serum ketones in symptomatic patients taking SGLT2 inhibitors even if blood glucose appears normal.